BMS Reports Three-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -743 Trial for 1L Treatment of Unresectable Malignant Pleural Mesothelioma

September 13, 2021 Auto Bot BMS, Clinical Trials, ipilimumab, Nivolumab, Opdivo, P-III, Yervoy 0

Shots:

  • The P-III CheckMate -743 trial evaluates Opdivo (3mg/kg, q2w) + Yervoy (1mg/kg, q6w) vs CT in 605 patients with previously untreated unresectable MPM. The results will be presented at ESMO 2021
  • The result showed an improvement in OS with a reduction in risk of death, patients were alive (23% vs 15%) @3yrs., improvement in m-OS (18.1 vs 14.1mos.), ORR (39.6% vs 44.0%), patients responded (28% vs 0%), m-DOR (11.6 vs 6.7mos.). The safety profile was consistent with previous data & no new safety signals were observed
  • The combination has been approved for unresectable MPM in 14 countries globally including the US, EU, Japan & China while other regulatory applications are under review globally

Click here to read full press release/ article | Ref: BMS | Image: Fierce Pharma

The post BMS Reports Three-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -743 Trial for 1L Treatment of Unresectable Malignant Pleural Mesothelioma first appeared on PharmaShots.